Biopharma financing during the third quarter of 2023 totaled $23.3bn from 238 deals. The debt category made up the greatest proportion (36%) of the aggregate Q3 financing dollars (see Exhibit 1), however, two outlier transactions accounted for 83% of the debt total.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?